Novartis’s investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial. Novartis is testing BAF312 against secondary progressive multiple sclerosis (SPMS), which includes patients ... Read More »